HDAC inhibitors have shown promising results in DLBCL cell lines via the upregulation of CD20, enhancing the efficacy of anti-CD20 monoclonal antibodies and promoting lymphoma cell apoptosis [117]. Here, HDAC9 is linked to diffuse large B-cell lymphoma.